Not currently recruiting at University of California Health
A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Zev Wainberg (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Zev Wainberg (ucla)
HS Clinical Professor, Medicine. Authored (or co-authored) 161 research publications
Details
- Status
- accepting new patients at some sites,
but this study is not currently recruiting here - Start Date
- Completion Date
- (estimated)
- Sponsor
- Eli Lilly and Company
- Links
- A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
- ID
- NCT06586515
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 530 study participants
- Last Updated